CENTRE FOR DOCTORAL TRAINING IN THE EPSRC CENTRE FOR INNOVATIVE MANUFACTURING IN EMERGENT MACROMOLECULAR THERAPIES

拟议的EPSRC CDT的重点将是英国生物中心制药和医疗保健生物技术部门发展最快的部分所需的制造研究和培训，这对未来的医学有重大影响。生物工艺工业生产新型大分子药物，蛋白质，以解决广泛的慢性和衰弱的人类疾病。英国凭借其科学基础处于领先地位，并拥有支撑该行业的独特大学能力。虽然收入很大，2009年在全球范围内约为1100亿英镑，但如果要满足降低成本和减少废物的需求，以及人们从强效药物中受益，那么该行业面临巨大的变革压力。如果现代药物的潜力要通过广泛的销售，在未来十年中制造业将需要一个巨大的变化。此外，这伊萨一个广泛接受的技能短缺的个人与制造研究培训所需的部门。对齐EPSRC中心的创新制造紧急高分子治疗将提供增加的国家能力，通过培训下一代的高技能和人才的生物过程制造研究人员。我们的目标是培养未来的生物过程工程领导者，他们将以可承受的成本将新的科学进步转化为安全生产，更具选择性的治疗方法。为了实现这一目标，我们将把CDT博士嵌入英国顶级机构和EPSRC紧急高分子治疗创新制造中心充满活力的研究社区，以确保他们从与研究主导公司的联系中受益。这些合作将使CDT能够在借鉴优秀研究成果的培训环境中探索新的和新兴的想法，并在中心研究计划之间建立强大的协同作用。

The focus of the proposed EPSRC CDT will be on manufacturing research and training required in the most rapidlydeveloping parts of the UK bio-centred pharmaceutical and healthcare biotechnology sector, that have major implicationsfor future medicine. The bioprocess industry manufactures novel macromolecular drugs, proteins, to address a broad rangeof chronic and debilitating human diseases. The UK holds a leading position by virtue of its science base and has unique university capabilities underpinning the sector. Whilst revenues are large, ~£110bn in 2009 on a worldwide basis, there arehuge pressures on the industry for change if demands for cost reduction and waste minimisation are to be met, andpopulations are to benefit from the potent drugs becoming available. A sea change in manufacturing will be needed overthe next decade if the potential of modern drugs are to make their way through to widespread distribution. Moreover this isa widely accepted skills shortage of individuals with the manufacturing research training needed for the sector.Alignment to the EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies will deliver increasednational capability through training of the next generation of highly skilled and talented bioprocess manufacturingresearchers. Our aim is to train bioprocess engineering leaders of the future who will underpin translation of new scientificadvances into safely produced, more selective, therapies for currently intractable conditions at affordable costs. To achievethis we will embed CDT PhDs within the vibrant research community of the top UK Institutions and that of the EPSRCCentre for Innovative Manufacturing in Emergent Macromolecular Therapies, to ensure that they benefit in terms of impactand knowledge transfer from the links to research led companies. The gearing in of these collaborations will enable theCDT to explore new and emerging ideas in a training environment that draws on research excellence and to create strongsynergy between the Centre research programmes.